How TMS Is Showing Promise for ALS, Parkinson’s, and Brain Inflammation
In a brief report from an international meeting in Rome that included Harvard faculty, the speaker highlights emerging, though still preliminary, data suggesting transcranial magnetic stimulation (TMS) may influence inflammatory and autoimmune processes linked to several neurodegenerative diseases. Strong signals of benefit are noted for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, and Parkinson’s disease—conditions that currently lack disease‑modifying therapies. The discussion points to ongoing studies examining how TMS affects lymphocytes, blood cells, and the inflammasome, positioning the immune‑modulatory aspect of TMS as the next major research frontier with the potential for impactful clinical results.
